Product image of Olmesartan/Hydrochlorothiazid Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Olmesartan/Hydrochlorothiazid Aurobindo

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Olmesartan/Hydrochlorothiazid Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Hydrochlorothiazid Aurobindo, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adults, often in combination with a diuretic. GNH India supplies Olmesartan/Hydrochlorothiazid Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Olmesartan/Hydrochlorothiazid Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Puren Pharma Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan/Hydrochlorothiazide is a combined antihypertensive agent that lowers blood pressure through dual mechanisms.

  • Hypertension: Improves blood pressure control when monotherapy is insufficient.
  • Heart failure: Assists in managing fluid overload as part of a broader regimen.
  • Diabetic nephropathy: Helps reduce proteinuria and protect renal function in patients with type 2 diabetes.
  • Stroke prevention: Contributes to secondary prevention of cerebrovascular events in hypertensive patients.
  • Chronic kidney disease: Supports blood pressure reduction to slow disease progression.
  • Post‑myocardial infarction: Aids in long‑term blood pressure management after an MI.

How It Works

  • Olmesartan medoxil selectively blocks the AT1 subtype of angiotensin II receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urinary excretion of water and electrolytes. Together they reduce peripheral vascular resistance and plasma volume, producing an additive antihypertensive effect.

Side Effects

Common Side Effects

  • Dizziness or light‑headedness, especially after the first dose.
  • Headache.
  • Fatigue.
  • Increased urination.
  • Electrolyte disturbances such as low potassium.
  • Mild gastrointestinal discomfort.

Serious or Rare Side Effects

  • Severe hypotension.
  • Acute kidney injury.
  • Hyperkalemia.
  • Angio‑edema involving the face, lips or tongue.
  • Pancreatitis.
  • Severe skin reactions such as Stevens‑Johnson syndrome.

Precautions & Warnings

Patients should be monitored for blood pressure response and renal function during therapy.

  • Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity risk.
  • Breastfeeding: Use only if the benefit outweighs potential risk to the infant.
  • Electrolyte monitoring: Check serum potassium and sodium regularly.
  • Renal impairment: Dose adjustment may be required; monitor creatinine.
  • Drug interactions: Review concomitant medications for additive hypotensive effects.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

  • Aliskiren in patients with diabetes or renal impairment.
  • Potassium‑rich supplements or potassium‑sparing diuretics (risk of hyperkalemia).
  • NSAIDs (may blunt antihypertensive effect and affect renal function).

Moderate Interactions (Monitor Closely)

  • Lithium (increased lithium levels).
  • Antidiabetic agents (enhanced hypoglycaemic effect).
  • ACE inhibitors or other ARBs (additive risk of hyperkalemia and renal dysfunction).

Frequently Asked Questions

Olmesartan/Hydrochlorothiazid Aurobindo is a fixed‑dose combination of an angiotensin II receptor blocker and a thiazide diuretic. It is prescribed to lower high blood pressure in adults, often when a single agent does not achieve target levels, and may be part of therapy for related cardiovascular conditions.

Olmesartan medoxil blocks AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. This leads to relaxed blood vessels and reduced blood pressure. The partner component, hydrochloride hydrochlorothiazide, increases urinary excretion of sodium and water, further lowering circulating volume.

The prescribed dose is individualized by the treating physician based on the patient’s blood pressure, response, and tolerability. The prescriber determines the appropriate strength and dosing schedule according to clinical guidelines.

Use during pregnancy, especially in the second and third trimesters, is contraindicated because of potential fetal harm. Breastfeeding is not routinely recommended unless the benefit to the mother outweighs possible risks to the infant, and it should be decided by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy using either an ARB or a thiazide alone, the Olmesartan/Hydrochlorothiazide combo offers additive blood‑pressure reduction, often achieving targets with fewer tablets. It may be preferred over ACE‑inhibitor‑diuretic combos when patients experience cough with ACE inhibitors.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or split unless advised.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, and angio‑edema. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or a rapid decline in kidney function.

Individuals with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation should avoid it. It is also contraindicated in pregnant women (second and third trimesters) and patients with severe renal impairment unless closely monitored.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT